Antipodean Advisors’s Cardlytics CDLX Stock Holding History

Antipodean Advisors’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$330K	Sell	2,000 -1,500	-43%	-$195K	1.69%	11
2023 Q2	$221K	Hold	3,500	–	–	1.57%	8
2023 Q1	$119K	Sell	3,500 -4,000	-53%	-$209K	0.74%	7
2022 Q4	$434K	Sell	7,500 -46,540	-86%	-$2.87M	1.45%	5
2022 Q3	$5.08M	Sell	54,040 -9,840	-15%	-$1.4M	13%	3
2022 Q2	$14.3M	Hold	63,880	–	–	23.22%	2
2022 Q1	$35.1M	Hold	63,880	–	–	25.43%	3
2021 Q4	$42.2M	Hold	63,880	–	–	17.33%	3
2021 Q3	$53.6M	Hold	63,880	–	–	15.18%	3
2021 Q2	$81.1M	Hold	63,880	–	–	22.33%	3
2021 Q1	$70.1M	Sell	63,880 -1,720	-3%	-$2.27M	21.66%	3
2020 Q4	$93.7M	Hold	65,600	–	–	26.3%	2
2020 Q3	$46.3M	Hold	65,600	–	–	16.94%	3
2020 Q2	$45.9M	Hold	65,600	–	–	21.19%	2
2020 Q1	$22.9M	Hold	65,600	–	–	21.17%	2
2019 Q4	$41.2M	Buy	65,600 +600	+0.9%	+$293K	23.59%	2
2019 Q3	$21.8M	Buy	65,000 +50,764	+357%	+$16.3M	18.17%	2
2019 Q2	$3.7M	Buy	+14,236	New	+$2.85M	4.5%	8

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

WPM

Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Antipodean Advisors's CDLX Position: Q3 2023 in Review

Antipodean Advisors reduced its Cardlytics (CDLX) stake by 43% in Q3 2023, selling an estimated $195K and leaving 2,000 shares worth $330K. The position accounts for 1.69% of the portfolio, ranked #11.

Antipodean Advisors first reported a position in CDLX in Q2 2019 and has held it in 18 quarters since. The position peaked at $93.7M in Q4 2020. 112 funds tracked by Wall St. Rank hold CDLX as of Q3 2023.

Antipodean Advisors held 2,000 shares of Cardlytics worth $330K as of Q3 2023.
Antipodean Advisors sold 1,500 Cardlytics shares in Q3 2023, an estimated $195K.
Cardlytics made up 1.69% of Antipodean Advisors's portfolio in Q3 2023, its #11 holding.
Antipodean Advisors first reported a position in Cardlytics in Q2 2019 and has held it in 18 quarters since.
Antipodean Advisors's Cardlytics position peaked at $93.7M in Q4 2020.
112 funds tracked by Wall St. Rank held Cardlytics as of Q3 2023.

Based on Antipodean Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.